David Gregory Lonergan

USPTO Granted Patents = 21 (Patent Applications = 6)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 6)

Average Co-Inventor Count = 3.0

ph-index = 4

Forward Citations = 55(Granted Patents)

Location History:

Ventura, CA (US) (2013 - 2016)
San Marcos, CA (US) (2010 - 2020)
San Diego, CA (US) (2020 - 2023)

Company Filing History:

Sabre Therapeutics LLC

Fosun Orinove Pharmatech, Inc.

patents

Years Active: 2010-2025

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12268668 - Autotaxin inhibitor compounds (2025-04-08),

2. 11779568 - Autotaxin inhibitor compounds (2023-10-10),

3. 11459309 - Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making (2022-10-04),

4. 11358936 - Lysyl oxidase-like 2 inhibitors and uses thereof (2022-06-14),

5. 11344533 - Autotaxin inhibitor compounds (2022-05-31),

6. 10774069 - Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making (2020-09-15),

7. 10766860 - Lysyl oxidase-like 2 inhibitors and uses thereof (2020-09-08),

8. 10688081 - Autotaxin inhibitor compounds (2020-06-23),

9. 10632104 - Autotaxin inhibitors and uses thereof (2020-04-28),

10. 9999615 - Autotaxin inhibitor compounds (2018-06-19),

11. 9981901 - IRE-1α inhibitors (2018-05-29),

12. 9951026 - Heterocyclic vinyl autotaxin inhibitor compounds (2018-04-24),

13. 9926318 - Tetracyclic autotaxin inhibitors (2018-03-27),

14. 9850203 - Autotaxin inhibitor compounds (2017-12-26),

15. 9714240 - Vinyl autotaxin inhibitor compounds (2017-07-25),

Title: David Gregory Lonergan: Innovator in Pharmaceutical Compounds

Introduction

David Gregory Lonergan, based in Ventura, California, is a notable inventor with an impressive portfolio of 20 patents. His contributions to the field of pharmaceuticals have made significant impacts, particularly in the development of innovative compounds aimed at treating various health conditions.

Latest Patents

Lonergan's latest patents include groundbreaking research on autotaxin inhibitor compounds. These patents describe various compounds that can inhibit autotaxin, along with methods of producing these compounds and pharmaceutical compositions that include them. Furthermore, his work encompasses the development of crystalline forms of a lysyl oxidase-like 2 inhibitor. This patent illustrates the various methods of production and the potential medicinal applications for the treatment of conditions related to LOXL2 activity.

Career Highlights

Throughout his career, David has collaborated with various esteemed institutions, most notably Pharmakea, Inc. and MannKind Corporation. His endeavors in these companies highlight his commitment to advancing pharmaceutical research and innovation. His experience has enabled him to develop valuable intellectual property that contributes significantly to modern medicine.

Collaborations

David has also worked alongside prominent professionals in the field, including John Howard Hutchinson and Martin W Rowbottom. These collaborations have facilitated the exchange of ideas and expertise, leading to the development of pioneering pharmaceutical solutions.

Conclusion

David Gregory Lonergan stands out as an influential inventor in the pharmaceutical arena. His innovative patents and collaborative spirit continue to drive advancements that promise to enhance the treatment of various diseases. His work exemplifies the importance of innovation in improving health outcomes and showcases the potential of patented inventions to transform the industry.

This text is generated by artificial intelligence and may not be accurate.